key: cord-1020246-3px8viqw
authors: Padhi, Aditya K.; Seal, Aniruddha; Khan, Javed Masood; Ahamed, Maqusood; Tripathi, Timir
title: Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations
date: 2020-12-31
journal: Eur J Pharmacol
DOI: 10.1016/j.ejphar.2020.173836
sha: 0f371d07f993097ee35f10245be9f9d2d992e6cc
doc_id: 1020246
cord_uid: 3px8viqw

The COVID-19 pandemic has spread rapidly and posed an unprecedented threat to the global economy and human health. Broad-spectrum antivirals are currently being administered to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). China's prevention and treatment guidelines suggest the use of an antiinfluenza drug, arbidol, for the clinical treatment of COVID-19. Reports indicate that arbidol could neutralize SARS-CoV-2. Monotherapy with arbidol is found to be superior to lopinavir-ritonavir or favipiravir for treating COVID-19. In SARS-CoV-2 infection, arbidol acts by interfering with viral binding to the host cells. However, the detailed mechanism through which arbidol induces the inhibition of SARS-CoV-2 is not known. Here, we present atomistic insights into the mechanism underlying membrane fusion inhibition by arbidol for SARS-CoV-2. Molecular dynamics (MD) simulation-based analyses demonstrate that arbidol binds and stabilizes at the receptor-binding domain (RBD)/ACE2 interface with a high affinity. It forms stronger intermolecular interactions with the RBD than ACE2. Analyses of the detailed decomposition of energy components and binding affinities revealed a substantial increase in the affinity between the RBD and ACE2 in the arbidol-bound RBD/ACE2 complex, suggesting that arbidol could generate favorable interactions between them. Based on our MD simulation results, we propose that the binding of arbidol induces structural rigidity in the viral glycoprotein, resulting in a restriction of the conformational rearrangements associated with membrane fusion and virus entry. Furthermore, key residues of the RBD and ACE2 that interact with arbidol were identified, opening the door for developing therapeutic strategies and higher-efficacy arbidol derivatives or lead drug candidates.

We are living through an unprecedented existential crisis. The rapid spread of the new coronavirus disease ) across all the continents over a short span of a few months has posed a severe global threat. In March 2020, the World Health Organization declared COVID-19 a pandemic, and by early December 2020, COVID-19 had spread to 218 countries and territories, with over 63 million confirmed cases and over 1.4 million deaths.

The causative pathogen of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents a serious threat to human health and the global economy. Shortly after the outbreak, the genome sequence and organization of SARS-CoV-2 were determined . SARS-CoV-2 is a large, enveloped, single-positive-strand RNA coronavirus (CoV). The envelope-anchored spike glycoprotein (S-protein) binds to the human angiotensin-converting enzyme 2 (ACE2) receptor, facilitating membrane fusion. Upon interaction, the S-protein/ACE2 complex undergoes structural rearrangements that allow for the fusion of viral and cellular membranes and entry into host cells.

The receptor-binding domain (RBD) of the S-protein is the central region that is involved in direct interactions with the ACE2 receptor. Several complex structures of RBD/ACE2 have been elucidated, and the interfacial residues have been identified (Lan et al., 2020; Wrapp et al., 2020) . A cryo-EM structure reveals the different conformational states of RBD, namely, the active open conformation, the semiactive conformation, and the closed state (Wrapp et al., 2020) . Structurally, the SARS-CoV-2 spikes consist of three receptor-binding S1 heads (responsible for receptor recognition) and a trimeric membranefusion S2 stalk (responsible for membrane fusion). The S1 is further divided into an Nterminal domain (NTD) and a C-terminal domain (CTD). An extended insertion contains the receptor-binding motif of RBD that contains most of the interfacial residues. The binding affinity of the RBD for ACE2 is the key determinant of SARS-CoV-2 transmissibility (Padhi et al., 2020a) . Interestingly, the SARS-CoV-2 RBD displays a stronger affinity for ACE2 than the RBD of other CoVs (Tai et al., 2020) , which is attributed to the higher number of residue interaction networks in SARS-CoV-2 with human ACE2 (hACE2). Thus, SARS-CoV-2 J o u r n a l P r e -p r o o f encodes distinct epitope features in the RBD from other CoVs. The blocking of the S-protein from ACE2 receptor interaction and cell fusion is among the key targets for antiviral development . The SARS-CoV-2 virus is not actively mutating; however, with time, it can acquire mutations with fitness advantages and develop resistance (Callaway, 2020; Padhi et al., 2020b; Padhi and Tripathi, 2020) .

To date, no clinically proven effective antiviral strategy exists for the treatment of COVID-19. Consequently, the management for SARS-CoV-2 is mostly supportive, with the only aim being mortality reduction. Clinicians are treating patients with ritonavir-lopinavir, hydroxychloroquine, azithromycin, corticosteroids, and interleukin-6 inhibitors outside their approved uses and without study protocols, with limited scientific evidence. However, an array of drugs approved for other viral infections are being studied for COVID-19 treatment in hundreds of clinical trials around the globe (Gordon et al., 2020; Guy et al., 2020; Horby et al., 2020; Rajarshi et al., 2020; . Recent data have indicated that remdesivir treatment could shorten the time to recovery in adults (Beigel et al., 2020) . However, another human trial showed that the drug did not help patients in China with severe COVID-19 (Wang et al., 2020d) . Several clinical trials are also underway to evaluate the suitability and efficacy of other antiviral drugs, such as favipiravir, darunavir, ribavirin, galidesivir, oseltamivir, arbidol, etc., for treating COVID-19 (De Clercq, 2004; Dong et al., 2020; Elfiky, 2020; Koren et al., 2003; Li et al., 2020; Rajter et al., 2020; Runfeng et al., 2020; Sarzi-Puttini et al., 2020; Tu et al., 2020; Velavan and Meyer, 2020; Wang et al., 2020a; Wu and Yang, 2020) .

Arbidol, also known as umifenovir, or ethyl-6-bromo-4-[(dimethylamino)methyl]-5hydroxy-1-methyl-2[(phenylthio)methyl]-indole-3-carboxylate hydrochloride monohydrate, is a small indole derivative. It is a potent broad-spectrum antiviral with proven activity against several enveloped and nonenveloped viruses, including influenza, parainfluenza, coronavirus, polio, Lassa fever, respiratory syncytial virus, adenovirus, Coxsackie B5, and hepatitis B and C (Blaising et al., 2014; Boriskin et al., 2008; Herod et al., 2019; Pecheur et al., 2016) . Arbidol has been used for decades in China and Russia for treating influenza and J o u r n a l P r e -p r o o f other respiratory viral infections with no major adverse effects (Blaising et al., 2014; Boriskin et al., 2008) . It suppresses influenza virus propagation and modulates the expression of inflammatory cytokines in vitro and in vivo (Wang et al., 2017) . Currently, arbidol use is recommended in China's prevention and treatment guidelines and is used in the clinical treatment of COVID-19. Arbidol interferes with multiple stages of the virus life cycle by directly targeting viral proteins or virus-associated host factors (Blaising et al., 2014) . In the influenza virus, arbidol binds to hemagglutinin (HA), the major cell-surface glycoprotein, and it prevents the fusion of the viral membrane (Kadam and Wilson, 2017) . A recent study revealed that arbidol efficiently inhibits SARS-CoV-2 infection. Arbidol blocks both viral entry (by interfering with viral binding to host cells) and postentry stages (by blocking intracellular vesicle trafficking) (Wang et al., 2020c) . However, the way through which arbidol modulates the RBD/ACE2 interaction has not been completely elucidated, thereby obscuring its development as specific therapeutics for COVID-19. Thus, we aimed to investigate the molecular basis underlying the RBD/ACE2 interaction inhibition using all-atom molecular dynamics (MD) simulations. Our data provide details on why arbidol is effective against SARS-CoV-2. The mechanistic understanding gained from this study would be useful in the design and development of more specific SARS-CoV-2 inhibitors.

The cocrystal structure of the SARS-CoV-2 RBD/ACE2 complex was retrieved from the RCSB Protein Data Bank (PDB ID: 6LZG) and used for molecular docking (Fig. 1A) . To start with, the arbidol was docked to ACE2 and J o u r n a l P r e -p r o o f RBD separately, and into the RBD/ACE2 complex. It could bind at several positions in all three conditions. However, since arbidol inhibits the SARS-CoV-2 membrane attachment to host cells, arbidol was docked into the RBD/ACE2 complex structure. During this process, twenty cavities were generated and used, and molecular docking was performed at each of the cavities. The binding modes were analyzed in cerebro, and the docked pose with the highest AutoDock Vina score and cavity size was selected for subsequent experiments.

From now on, the RBD/ACE2 complex without arbidol will be termed the "apo-RBD/ACE2

complex", and the RBD/ACE2 complex bound to arbidol will be named as the "RBD/ACE2arbidol complex".

The selected docked complex of RBD/ACE2-arbidol was prepared using Schrödinger Maestro (Schrödinger Release 2016-4: Maestro, Schrödinger, New York) and subsequently used for the MD simulations. As a first step, the topology of arbidol was generated using Automated Topology Builder and Repository, and the resulting complex was subjected to the addition of hydrogen atoms (Koziara et al., 2014; Malde et al., 2011) . Next, the complex was solvated in a dodecahedron box with simple point charge water in the center at least 1.0 nm from the box edge (Berendsen et al., 1981) . Appropriate counterions were then added to neutralize the system electrostatically. MD simulations for the resulting system were performed using the GROMACS 5.1.2 software package with the gromos96 54A7 forcefield (Huang et al., 2011; Liu et al., 1996; Schmid et al., 2011) . The system was subjected to 50,000 energy minimization steps until the energy was stabilized, followed by a heating step from 0 to 300 K in 200 picoseconds (ps) and a constant temperature equilibration for 1000 ps at 300 K. During the equilibration stage, velocity impact was prevented by employing Parrinello-Rahman barostat pressure coupling (Parrinello and Rahman, 1981) . After monitoring the convergence of the complex, a 300 nanosecond (ns) production run was performed with periodic boundary conditions in the NPT ensemble, in which a modified

Berendsen temperature coupling and a constant pressure of 1 atm was employed (Bussi et J o u r n a l P r e -p r o o f al., 2007) . During this process, the LINCS algorithm and the particle mesh Ewald method were used to calculate the long-range electrostatic forces (Darden et al., 1993; Hess et al., 1997) . During the simulation, the Fourier grid spacing and Coulomb radius were set at 0.16 and 1.4 nm, respectively, and the van der Waals interactions were limited to 1.4 nm. The MD simulated trajectories were saved every 10 ps for energy stabilization. As a series of experiments, to understand the dynamics between RBD and ACE2 in the absence of arbidol, the simulation for the apo system was performed under similar conditions for 300 ns.

The MD simulated trajectories were analyzed using the gmx rms, gmx rmsf, and gmx gyrate GROMACS utilities to obtain the root mean square deviation (RMSD), root mean square fluctuation (RMSF), and radius of gyration (Rg) of each system, respectively. The hydrogen bonds for the apo-RBD/ACE2 complex and RBD/ACE2-arbidol complex were computed using the hydrogen bond plug-in in visual molecular dynamics (VMD) (Humphrey et al., 1996) .

To understand the dominant and collective modes from the overall dynamics of the MD trajectory for the apo-RBD/ACE2 complex and the RBD/ACE2-arbidol complex, a principal component analysis (PCA) and essential dynamics were performed using the protein backbones, during which a variance/covariance matrix was constructed by calculating the eigenvectors and eigenvalues and their projection along with the first two principal components (PCs) by essential dynamics (Amadei et al., 1993) . was computed using the gmx sham package from the first two eigenvectors extracted after PCA (Brooks et al., 2001; Mitsutake et al., 2001) .

To calculate the binding free energies between the RBD-arbidol, ACE2-arbidol, and RBD-ACE2-arbidol complexes, the molecular mechanics/Poisson-Boltzmann surface area (MM-PBSA) methodology employed in the g_mmpbsa tool of GROMACS was used (Homeyer and Gohlke, 2012; Kumari et al., 2014) . In the MM-PBSA, the binding free energy of the protein and ligand is typically defined as

where ΔG complex , ΔG protein , and ΔG ligand represent the total free energies of the protein, the ligand, and the protein-ligand complex, respectively, measured separately in the solvent (Gohlke et al., 2003; Wang and Kollman, 2000) . In general, the free energy of the individual entity is represented as

where E MM represents the average molecular mechanic potential energy in the vacuum, G solvation denotes the free energy of solvation, and TS represents the entropic contribution to the free energy in a vacuum, where T and S denote the temperature and entropy, respectively. Furthermore, the E MM comprises bonded and nonbonded terms, including the bond angle, torsion, and electrostatic (E elec ) and the van der Walls (E vdw ) interactions. Last, the solvation free energy, and the G solvation considers both electrostatic and nonelectrostatic 

The figures were rendered and generated using PyMOL and VMD. Ligand interaction diagrams were generated using Schrödinger Maestro (Schrödinger Release 2016-4:

Maestro, Schrödinger, New York).

J o u r n a l P r e -p r o o f 3. Results

Arbidol inhibits SARS-CoV-2 membrane fusion to host cells, suggesting that it targets Sprotein/ACE2 interactions. Since the RBD of S-protein is involved in ACE2 recognition, arbidol was docked into the RBD/ACE2 complex structure. When arbidol was docked into ACE2 and RBD separately, it was not docked at the ACE2 and RBD binding interface ( Supplementary Fig. 1) . Moreover, the largest cavities where arbidol was docked were not at the interface of the RBD side (facing ACE2) or the ACE2 side (facing RBD) ( Supplementary   Fig. 1 ). When this drug was docked into the RBD/ACE2 complex, it quickly docked into one of the largest cavities in the RBD/ACE2 interface with a high score [cavity size: 940, center:

176*114*247 (x*y*z) and size: 22*22*22 (x*y*z)]. Arbidol was found to bind and stabilize at the RBD/ACE2 interface with a high binding affinity (AutoDock Vina score of -5.7) (Fig. 2) .

The docked complex was subsequently used to study the detailed structural, dynamic, and binding mechanisms to understand how it targets the RBD/ACE2 interface.

The MD simulation trajectories comprising 300 ns of independent simulations for the apo-RBD/ACE2 complex and the RBD/ACE2-arbidol complex were examined for their structural and dynamic behaviors. The RMSD of the backbone atoms computed over 300 ns revealed that the apo-RBD/ACE2 complex reached stability after approximately 75 ns, whereas the formed 247 hydrogen bond interactions on average during the 300 ns simulations (Fig. 3B ).

This result indicated that the hydrogen bonds probably play an essential role in stabilizing the RBD/ACE2-arbidol complex during the simulation and confer stability to the RBD/ACE2arbidol complex.

The structural flexibility of the apo-RBD/ACE2 complex and arbidol bound complex was evaluated by computing the per-residue RMSF. As expected, the RBD/ACE2-arbidol complex exhibited an overall lower RMSF compared to the apo-RBD/ACE2 complex ( Fig. 3C and 3D). While the apo-RBD/ACE2 complex showed an average RMSF of 2.49 Å, the RBD/ACE2-arbidol complex showed a lower 1.67 Å average RMSF during the simulation, corroborating the RMSD and hydrogen bond interaction profiles ( Fig. 3C and 3D ). We were then curious to investigate how the two molecular systems displayed their compactness during the simulations. For this reason, we computed the Rg for both complexes over the 300 ns period. It was evident from the Rg profiles that the RBD/ACE2-arbidol complex exhibited a more compact behavior compared to the apo-RBD/ACE2 complex (Fig. 3E ). The

average Rg values were found to be 5.29 Å and 3.27 Å for the apo-RBD/ACE2 complex and the RBD/ACE2-arbidol complex, respectively. Interestingly, the Rg profile of the RBD/ACE2arbidol complex was found to be more stable than the apo-RBD/ACE2 complex due to a higher number of favorable interactions. All these data indicate that the formation of more hydrogen bonds, reduced per-residue fluctuation, and higher compactness in the RBD/ACE2-arbidol complex drive its overall stability and convergence.

The PCA is an important technique that can provide insights into the correlation of atomic movements in enzyme and substrate interactions, which originate from the collective motion of atoms controlled by the secondary structures of the proteins. Typically, the largest J o u r n a l P r e -p r o o f associated eigenvalues define the essential subspace, in which most of the protein dynamics occur. For this purpose, the clusters of stable PCA states for the apo-RBD/ACE2

and RBD/ACE2-arbidol complexes were visualized and analyzed ( Supplementary Fig. 2 ).

The trace values calculated from the covariance matrix of the apo-RBD/ACE2 and RBD/ACE2-arbidol complexes were found to be 80.76 nm 2 and 69.51 nm 2 , respectively, suggesting that the RBD/ACE2 complex was subject to compaction upon arbidol binding.

However, a higher trace value for the apo-RBD/ACE2 complex suggested a comparatively high flexible behavior. It was also observed that the majority of the dynamics came from a small number of eigenvectors representing the overall collective motions. It was found that the percentage contribution of the first two eigenvectors can describe more than 80% and 90% of the total dynamics for the apo-RBD/ACE2 complex and the RBD/ACE2-arbidol complex, respectively. Next, the Gibbs FEL plots were generated from the principal component1 (PC1) and principal component (PC2) coordinates, where the blue, green, and cyan color represented metastable conformations with a low-energy state, while red color signified high-energy protein conformation. In the FEL plots, the ∆G value of the apo-RBD/ACE2 and RBD/ACE2-arbidol complexes ranged from 0-15.8 kJ/mol (Fig. 4) . This further demonstrates that the two systems behaved in a comparatively different manner during the simulations.

To investigate how strongly arbidol binds with ACE2 and the RBD and its associated binding modes, the binding free energies were computed using the MM-PBSA method. To this end, the last 30 ns of the MD simulation trajectories were investigated to obtain the binding affinities and insights into the binding mechanisms of arbidol. The arbidol was found to display a binding affinity of -73.36 kJ/mol to ACE2 (Table 1 ). The detailed decomposition of the energy components revealed that except for the polar solvation energy, the van der Waals energy and SASA energy contributed to the tighter binding of arbidol with ACE2.

When the binding affinity of arbidol was computed against the RBD, arbidol exhibited an J o u r n a l P r e -p r o o f even higher affinity of -105.95 kJ/mol with RBD than with ACE2 (Table 1 ). An energy decomposition profile further revealed similar energy components to that of ACE2; however, the van der Waals and polar solvation energies both were found to positively contribute towards tighter binding with RBD as compared to ACE2. The electrostatic energy played a comparatively minor role in binding. A molecular interaction obtained from an average structure of the MD simulations supported the binding mechanism of the arbidol to RBD/ACE2 complex (Fig. 5A) . Additionally, the well-superimposed structures of arbidol in the RBD/ACE2 interface obtained from the last 30 ns simulation further confirmed the stability and preferred binding mechanism (Fig. 5B) . Only the thio-phenyl group appeared to be slightly flexible in a few snapshots. From the detailed binding free energy calculations and a visual assessment, it can be concluded that arbidol has a higher binding affinity towards RBD, probably due to the establishment of a higher number of favorable interactions with the surrounding key residues.

Following the estimation of arbidol binding affinities towards ACE2 and RBD, we identified the critical residues in ACE2 and RBD that positively and negatively impacted arbidol binding. First, the contribution energy of individual interacting residues on ACE2 revealed that the residues Lys26, Asp30, His34, Val93, Ala387, Pro389, and Phe390 contributed the most toward the ACE2 affinity toward arbidol (Fig. 6A ). In addition, arbidol showed an even higher binding affinity towards RBD, in which many residues positively contributed towards its tighter binding. It was found that an array of residues such as Arg403, Asp405, Glu406, Gln409, Gly416, Lys417, Ile418, and Tyr505 contributed towards the higher binding of RBD towards arbidol (Fig. 6B) . Interestingly, they were also found to be a part of the ACE2-RBD interface interacting residues, which further confirms that arbidol binds and inhibits the interfacial residues of the RBD/ACE2 complex, where it established more contacts and interactions with the RBD compared to the ACE2 receptor. Furthermore, to understand the intermolecular interactions between arbidol and the RBD/ACE2 complex, representative J o u r n a l P r e -p r o o f structures were extracted from the MD simulation trajectory and analyzed. It was observed that while arbidol established few intermolecular interactions with the residues of ACE2, it formed a relatively higher number of crucial interactions with RBD. Overall, the analysis of the RBD/ACE2-arbidol complex interactions provided information on the vital residue interactions and gave insights into the differences between ACE2-arbidol and RBD-arbidol binding and its inhibitory mechanism.

Next, we computed the binding affinity using PRODIGY for the apo-RBD/ACE2 complex and the RBD/ACE2-arbidol complex extracted from MD simulations. We found that the RBD/ACE2-arbidol complex exhibited a higher binding affinity (ΔG) of -11.5 kcal/mol, whereas the apo-RBD/ACE2 complex exhibited a relatively lower binding affinity (ΔG) of -10.8 kcal/mol. We observed that the higher binding affinity in the RBD/ACE2-arbidol complex was due to an increase in the number of intermolecular, charged-polar, charged-apolar, and apolar-apolar contacts. The detailed decomposition of intermolecular contacts governing the difference in binding energies is shown in Table 2 . PPCheck was also used to compute the total stabilizing energy and the types of interactions in the apo-RBD/ACE2 and RBD/ACE2arbidol complexes, as extracted from MD simulations. The total stabilizing energy for the apo-RBD/ACE2 complex was -113.46 kJ/mol, and it was -171.57 kJ/mol for the RBD/ACE2arbidol complex (Table 3) . A closer inspection of interactions and energy components revealed that the hydrogen bonds and van der Waals pairs contributing to the hydrogen bond and van der Waals energies largely governed the difference in the total stabilizing energy and between the affinity of the RBD/ACE2 complex in its apo-RBD/ACE2 and RBD/ACE2-arbidol complexes (Table 3) .

The COVID-19 pandemic heightens the need for preparedness to respond to emerging virus threats rapidly (Mishra and Tripathi, 2020) . No therapies have been shown to be clinically effective to date. To assist in efforts to control the rapidly evolving pandemic, drug repurposing is being employed as an effective and fast method. Given the urgency of the situation, scientists must understand and characterize the molecular mechanisms of action

for the repurposed drugs being tested for COVID-19 treatment. A computational understanding of the molecular mechanisms underlying unproven anti-COVID-19 drugs may guide scientists toward developing a specific therapeutic against SARS-CoV-2.

Arbidol, a broad-spectrum antiviral drug, is currently being used as a standard treatment option for COVID-19 (Anonymous, 2020; Hulseberg et al., 2019; Pei-Fang, 2020; Pshenichnaya et al., 2019) . It shows significant antiviral and anti-inflammatory efficacy both in vitro and in vivo against the influenza virus (Wang et al., 2017) . Since the SARS-CoV-2 and influenza viruses exhibit similar disease pathologies, it is expected that arbidol could present anti-SARS-CoV-2 activity. Arbidol is patented for its medicinal use as an antiviral agent against atypical pneumonia induced by SARS-CoV (http://www.arbidol.org/arbidol-patent-2004-sars-russian.pdf). It has been found to inhibit SARS-CoV-2 effectively at a concentration of 4.11 µM in vitro, suggesting its potential in treating COVID-19 patients (Wang et al., 2020c) . Presently, at least four clinical trials are being conducted with arbidol as a single agent for COVID-19 treatment. A few case reports have shown that patients with COVID-19 successfully recovered after receiving arbidol and lopinavir/ritonavir therapy (Lim et al., 2020; Wang et al., 2020e) . Arbidol has been shown to be superior to the antiviral favipiravir, which did not improve the clinical recovery rate at Day 7 compared to that in the arbidol group . A recent result of a clinical trial in China indicated that arbidol monotherapy is also superior to lopinavir/ritonavir at treating COVID-19 (Zhu et al., 2020) . A study with a small sample size reported that arbidol could not improve the prognosis of COVID-19 in non-ICU patients; however, that study was preliminary and limited by several factors because i) the research was a single-center and retrospective study, ii) pharyngeal swabs were not collected every day, and iii) it only J o u r n a l P r e -p r o o f included patients with moderate and severe COVID-19, so the efficacy of arbidol in mild and critical patients could not be confirmed (Lian et al., 2020) . Arbidol binds to the interface of the viral glycoprotein and human cell surface receptors, thereby blocking membrane fusion and viral entry (Boriskin et al., 2008; Leneva et al., 2009; Pécheur et al., 2007; Teissier et al., 2011) . The binding of arbidol is topologically away from the active site of the ACE2 receptor.

In SARS-CoV-2, arbidol acts by interfering in virus binding to host cells (Wang et al., 2020c) .

A few molecular docking studies on arbidol against the SARS-CoV-2 RBD and human ACE2

complex have revealed the specific residues involved in the interaction; however, the detailed mechanism underlying the process and the associated dynamics are not known (Barik et al., 2020; Vankadari, 2020) .

Our analyses of the 300 ns MD simulation trajectories revealed that when arbidol was docked in the RBD-ACE2 complex interface, it stabilized and formed favorable interactions with both RBD and ACE2 proteins. However, arbidol displayed a higher binding affinity to RBD than ACE2. The analysis of hydrogen bonds revealed that following arbidol binding, the RBD/ACE2 complex could form a higher number of hydrogen bond interactions compared to the apo-RBD/ACE2 complex. The binding also induced structural rigidity and compaction in the RBD/ACE2-arbidol complex. The compaction was also confirmed by the PCA analyses, in which the RBD/ACE2-arbidol complex formed a more stable cluster. The detailed decomposition of energy components revealed that the binding of arbidol to ACE2 is due to positive contributions from the van der Waals energy, electrostatic energy, and SASA energy, while the tighter binding of arbidol to RBD is primarily due to positive contributions from the van der Waals energy and polar solvation energy. Furthermore, arbidol binding leads to a substantial increase in the binding affinity between RBD and ACE2, indicating that arbidol induced favorable interactions between them. Overall, the data indicated that arbidol binding drives an increase in the structural stability, compactness, and convergence of the RBD/ACE2 complex. In the absence of any arbidol-bound structure of RBD/ACE2 complex, our data offer the hypothesis that arbidol binding to the interface of viral glycoprotein and J o u r n a l P r e -p r o o f human receptors induces structural rigidity, leading to the inhibition of the conformational changes in the S-protein that is associated during viral entry.

The Chinese Center for Disease Control and Prevention recommends arbidol, an antiinfluenza drug, for the management and treatment of COVID-19. Arbidol has been found to be superior to other antiviral combinations. In SARS-CoV-2, arbidol acts by interfering in viral binding to host cells. However, the detailed mechanism is not known. To develop effective therapeutics or higher-efficacy arbidol derivatives, there is an ample need to gain insights into its mechanisms of action. With guidance from MD simulations and structure network analysis, we demonstrate that arbidol binds at the RBD/ACE2 interface, establishing stronger intermolecular interactions with RBD and inducing favorable interactions between them, resulting in an increased affinity between RBD and ACE2. Arbidol binding may induce structural inflexibility, leading to inhibition in the conformational dynamics required during virus entry. Our study provides a first-hand explanation of why arbidol is effective against SARS-CoV-2. We highlight discrete regions in the interaction interface that could be potentially druggable pockets to destabilize the RBD/ACE2 complex. The mechanistic understanding gained from this study would be useful for the design and development of additional specific SARS-CoV-2 inhibitors. and docking score after molecular docking simulation. The blue, green, and cyan colors represent the metastable conformations with low-energy states, while the red color signifies the high-energy protein conformations. J o u r n a l P r e -p r o o f

Essential dynamics of proteins

Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment

Molecular docking and binding mode analysis of selected FDA approved drugs against COVID-19

Remdesivir for the treatment of Covid-19 -Final Report

Interaction models for water in relation to protein hydration

Arbidol as a broad-spectrum antiviral: an update

Arbidol: a broad-spectrum antiviral compound that blocks viral fusion

Statistical thermodynamics. Taking a walk on a landscape

Canonical sampling through velocity rescaling

Making sense of coronavirus mutations

Favipiravir versus arbidol for COVID-19: a randomized clinical trial

Particle mesh Ewald: An N⋅ log (N) method for

Antivirals and antiviral strategies

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

Anti-HCV, nucleotide inhibitors, repurposing against COVID-19

Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

The broad-spectrum antiviral drug arbidol inhibits foot-and-mouth disease virus genome replication

LINCS: a linear constraint solver for molecular simulations

Free energy calculations by the molecular mechanics poisson-boltzmann surface area method

Dexamethasone in hospitalized patients with Covid-19 -Preliminary Report

Validation of the GROMOS 54A7 force field with respect to β-peptide folding

Arbidol and other lowmolecular-weight drugs that inhibit lassa and ebola viruses

VMD: visual molecular dynamics

Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol

Ribavirin in the treatment of SARS: A new trick for an old drug?

Testing and validation of the automated topology builder (ATB) version 2.0: prediction of hydration free enthalpies

g_mmpbsa--a GROMACS tool for high-throughput MM-PBSA calculations

Performance of HADDOCK and a simple contact-based protein-ligand binding affinity predictor in the D3R Grand Challenge 2

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Characteristics of arbidolresistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol

Updated approaches against SARS-CoV-2

Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study

Case of the index patient who caused tertiary transmission of COVID-19 infection in korea: the application of lopinavir/ritonavir for the treatment of COVID-19 Infected pneumonia monitored by quantitative RT-PCR

Estimating the relative free energy of different molecular states with respect to a single reference state

CB-Dock: a web server for cavity detection-guided protein-ligand blind docking

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

An automated force field topology builder (ATB) and repository: version 1.0

One year update on the covid-19 pandemic: where are we now?

Generalized-ensemble algorithms for molecular simulations of biopolymers

High throughput designing and mutational mapping of RBD-ACE2 interface guide non-conventional therapeutic strategies for COVID-19

Rational design of the remdesivir binding site in the RNA-dependent RNA polymerase of SARS-CoV-2: implications for potential resistance

Can SARS-CoV-2 accumulate mutations in the s-protein to increase pathogenicity?

Polymorphic transitions in single crystals: A new molecular dynamics method

The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses

Biochemical mechanism of hepatitis C virus inhibition by the broadspectrum antiviral arbidol

Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7)

Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR)

Essential functional molecules associated with SARS-CoV-2 infection: Potential therapeutic targets for COVID-19

Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The ICON study

Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)

COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?

Definition and testing of the GROMOS force-field versions 54A7 and 54B7

Oligomerisation status and evolutionary conservation of interfaces of protein structural domain superfamilies

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis

A review of SARS-CoV-2 and the ongoing clinical trials

Contacts-based prediction of binding affinity in proteinprotein complexes

Large-scale prediction of binding affinity in protein-small ligand complexes: the PRODIGY-LIG web server

Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein

The COVID-19 epidemic

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Structural and functional basis of SARS-CoV-2 entry by using human ACE2

Free energy calculations on dimer stability of the HIV protease using molecular dynamics and a continuum solvent model

The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro

Inhibition of the infectivity and inflammatory response of influenza virus by Arbidol hydrochloride in vitro and in vivo (mice and ferret)

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet 395, 1569-1578. and Western medicine treatment

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

PRODIGY: a web server for predicting the binding affinity of protein-protein complexes

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

The author (MA) is grateful to the Researchers Supporting Project number (RSP-2020/129),

The authors declare no conflict of interests. complex and RBD/ACE2-arbidol complex from the last 30 ns MD simulation trajectories.

Apo-RBD/ACE2